I. Loyola

Recombinant human GM-CSF enhances T cell-mediated cytotoxic function after ABMT for hematological malignancies.

C. Richard, M. J. Alsar, R. Rios, 1993, Bone marrow transplantation.

Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) administration after autologous bone marrow transplantation for acute myeloblastic leukemia enhances activated killer cell function and may diminish leukemic relapse.

C. Richard, M. J. Alsar, M. A. Cuadrado, 1995, Bone marrow transplantation.

Invasive pulmonary aspergillosis prior to BMT in acute leukemia patients does not predict a poor outcome.

C. Richard, I. Romon, E. Conde, 1993, Bone marrow transplantation.

Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project.

L. Villalón, A. Acedo, A. Bárez, 2018, Blood cells, molecules & diseases.

Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project.

L. Villalón, A. Acedo, A. Bárez, 2018, Blood cells, molecules & diseases.

Substrate Reduction Therapy With Miglustat In Type 1 Gaucher Disease In Spain. Nine Years Outcomes Update On ZAGAL Study

L. Villalón, A. Bárez, E. Luño, 2013 .